[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"intermediate-risk-prostate-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:intermediate-risk-prostate-cancer":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,54],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100623225","phase-2-androgen-responsive-posluma-guided-intra-prostatic-boost-100623225",false,"NCT07393867","Androgen-responsive POSLUMA-guided Intra-prostatic Boost","Androgen-responsive POSLUMA-guided Intra-prostatic Boost (ARPEGGIO)","ARPEGGIO","Inclusion Criteria:\n\n* 18 years of age and older.\n* Eastern Oncology Group Status 0 to 1.\n* Histologic diagnosis of prostate cancer.\n* Prior screening MRI with at least one PI-RADS4 or PI-RADS 5 lesion, obtained within 180 days of screening.\n* NCCN intermediate-risk or high-risk prostate cancer (Appendix B). All patients will be staged by MRI.\n* Prior PSMA PET scan with at least one focal avid lesion greater than background prostate that is concordant with a lesion on MRI, obtained within 180 days of screening.\n* Intention for SBRT (36.25 Gy\u002F5 fraction) with focal boost (up to 50 Gy) to one MRI\u002FPET-concordant lesion34.\n\nExclusion Criteria:\n\n* Prior imaging (CT, bone scan, MRI, PSMA-PET\u002FCT) showing nodal or distant disease.\n* Intention to receive treatment intensification with secondary androgen receptor signaling inhibitors or chemotherapy.\n* Clinical T4 disease.\n* Prior ADT.\n* Prior pelvic RT.\n* Prior prostate surgery, including TURP.\n* International prostate symptom score \\> 20.\n* Prior urethral stricture.\n* Prostate volume \\> 80 cc on MRI.\n* Hip implants that cause artifacts over the prostate gland.\n* Inability to discontinue anti-coagulation for fiducial marker placement.\n* Active Crohn's disease or scleroderma.","MALE","18 Years",{"count":20,"type":21},23,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This research study is for men with intermediate- or high-risk prostate cancer who are planning to receive hormone therapy and radiation treatment. The purpose of the study is to see whether a special type of diagnostic imaging done during hormone therapy can help doctors more accurately target remaining cancer with radiation, while avoiding areas that may no longer need extra treatment. All participants will receive standard hormone therapy and radiation therapy, along with three imaging scans, over a six-month period. The information gained from this study may help make prostate cancer radiation treatment more precise and reduce side effects for future patients.",[27,28,29],"Intermediate Risk Prostate Cancer","High Risk Prostate Cancer","Prostate Cancer",[31,32,33,34,35,36,37,38,39,40],"POSLUMA","prostate-specific membrane antigen positron-emission tomography","PSMA-PET\u002FCT","18F-flotufolastat-PSMA-PET\u002FCT scan","ADT and 18F-flotufolastat-guided focal SBRT microboost","androgen deprivation therapy and 18F-flotufolastat-guided focal SBRT microboost","neoadjuvant ADT","neoadjuvant androgen deprivation therapy","neoadjuvant ADT prior to SBRT","18F-flotufolastat-PET\u002FCT scans for intermediate and high risk prostate cancer","RECRUITING","2026-05-27",{"date":44,"type":45},"2026-05-29","ACTUAL",{"date":47,"type":45},"2026-04-29",{"date":49,"type":21},"2027-12-15",{"name":51,"class":52},"Martin T. King, MD, PhD","OTHER",4,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":62,"targetDuration":4,"studyType":22,"phases":64,"briefSummary":66,"conditions":67,"keywords":70,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":88},"100525078","the-precision-study-3-fractions-of-prostate-sbrt-and-raypilot-hypocath-image-guidance-100525078","NCT06117059","The PRECISION Study: 3 Fractions of Prostate SBRT and RayPilot HypoCath Image Guidance","The PRECISION Study: A Phase II Study of 3 Fractions of Prostate SBRT With RayPilot System and HypoCath Image Guidance for Men With NCCN Low or Intermediate Risk Prostate Cancer","PRECISION","Inclusion Criteria:\n\n* low and favorable intermediate NCCN Criteria patients\n* Prostate volume under 80cc\n* IPSS under 20\n* Q-max above 10cc per second and urinary residual less than 150mls\n* No TURP\n* No hip replacements\n* No previous radiotherapy to the pelvis\n* No active second malignancy except skin SCC or BCC for the last 2 years\n* No history of inflammatory bowel disease\n* No co-morbid illness that would make compliance to treatment difficult\n* Able to give informed consent\n\nExclusion Criteria:\n\n* T3a or above\n* Gleason 4+3=7\n* PSA\\>20ng\u002Fml",{"count":63,"type":21},100,[65],"NA","The investigators want to investigate whether it is possible to reduce the number of curative radiotherapy doses from 5 to only 3 for men with localized early prostate cancer. The aim of the study is to ensure that the side effects of the 3-dose treatment are the same or potentially lower than those already published when using the 5-dose treatment as used in the UK PACE-B trial (NCT01584258). The name of this type of radiotherapy is Stereotactic Body Radiotherapy (SBRT) or participants may see it referred to as Stereotactic Ablative Radiotherapy (SABR). The study is a two-stage single arm Phase II study open to those Centres that use the RayPilot HypoCath tumour tracking system (Micropos Medical). This commercially available system was not available at the time of the original PACE-B study. The system acts like a Global Positioning Device (GPS) to continuously track the prostate position during radiotherapy. If the prostate moves more than 2mm (about 0.08 in) from its intended position during the treatment, then the radiotherapy team are alerted, and the treatment halted until the prostate moves back into the correct position. The ability to understand exactly where the prostate is throughout the treatment ensures the intended dose hits the cancer and does not accidentally increase the dose to the nearby bladder and rectum. The system is a modification of a standard urinary catheter which sits within the bladder with the GPS placed within the wall of the catheter as it passes through the prostate. The investigators are not testing the system as it is commercially available but using it to improve the accuracy of radiotherapy delivery, reducing the number of days of treatment, minimizing side effects and helping ease the burden on busy radiotherapy Departments.",[68,69,27],"Localized Prostate Cancer","Low Risk Prostate Cancer",[71,72,73,74,75,76,77],"SBRT","SABR","PROSTATE CANCER","RayPilot","HypoCath","Continuous tracking","3 fractions","2026-01-08",{"date":80,"type":45},"2026-01-12",{"date":82,"type":45},"2024-11-01",{"date":84,"type":21},"2027-11-01",{"name":86,"class":87},"NHS Lothian","OTHER_GOV",1]